EVRONIXTM
Everolimus-Eluting Coronary Stent


mukam

Features

  • Unique stent design and strut locking mechanism offers excellent radial strength and minimum recoil.
  • L 605 cobalt chromium stent platform with hybrid cell design.
  • Improved stent apposition and uniform neointimal coverage.
  • Completely biodegradable, biocompatible polymer (PLGA carrier)-loading density of 1.2ug/mm2.
  • 6μm uniform coating thickness with precisely programmed releasekinetics.
  • 95+5% of everolimus is released within 120 days.
  • Inhibits In-stent restenosis (ISR) and late thrombosis with adequatere-endothelization within 90 days.
  • Tappered design stent and delivery system.
  • Designed for utmost safety-Evronix displays one of the lowest entry profiles.
  • Hydrophilic coated stent delivery system.
Download Brochure

Technical Specifications

Parameter Specification
Available stent lengths 10, 13, 15, 18, 20, 24, 28, 32, 36, 40, 42 & 44 mm
Available stent diameters 2.25, 2.50, 2.75, 3.00, 3.50 & 4.00 mm
Stent material L605 Cobalt-chromium (Co-Cr) alloy
Stent design Hybrid
Stent platform Cobal + Cr
Stent strut thickness 65 μm
Stent foreshortnening <2%
Recoil <4%
Drug Everolimus
Delivery system Hydrophilic Coated
Polymer Type Biodegradable (PLGA)
Coating Thickness 6 μm

In Vitro release kinetics of Evronix

  • More than 60% of drug is released in 4 weeks.
  • Remaining drug is released for about 12 weeks.